Reversing Neuropathy

Regenacy’s HDAC6 inhibitor is a disease-modifying therapy for neuropathies

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy.

Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016 acquisition by Celgene Corp. with rights to develop ricolinostat in some non-cancer indications. Celgene has ricolinostat in Phase I/II trials to treat lymphoma and multiple

Read the full 600 word article

How to gain access

Continue reading with a
two-week free trial.